lystn

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Are You Providing The Most Up To Date Care in Moderate-to-Severe Atopic Dermatitis?Featuring Anna Yasmine Kirkorian, MD as faculty, moderated by Brad P. Glick, DO, MPH, FAAD.Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and spongiotic dermatitis that severely impacts quality of life (QoL) and places a heavy burden on patients and families. Many patients, particularly those with moderate-to-severe AD, are inadequately managed by conventional therapies and may require treatment with newer targeted agents to achieve treatment success. New and emerging therapies are revolutionizing the management of AD and are changing the treatment paradigm by offering a personalized approach to management. Dermatologists and allergists play key roles in guiding the selection and use of newer therapies in appropriate patients and will benefit from increased familiarity with new treatments and evidence-based guidelines. This podcast was recorded and is being used with the permission of the presenters. Learning Objectives Upon completion of this activity, learners should be able to: Recognize the burden of moderate-to-severe atopic dermatitis (AD), and the importance of patient and caregiver education for optimal management. Implement individualized treatment strategies for patients with moderate-to-severe AD, based on guideline recommendations, data on new and emerging treatments, management of comorbidities, and optimization of quality of life. This activity is accredited for CME/CE credit.  For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Are You Providing The Most Up To Date Care in Moderate-to-Severe Atopic Dermatitis?The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hour (which includes 0 hours of pharmacology).This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.For more info on this topic, join NACE on June 5, 2021 for our live Conversations in Dermatology virtual program  with Drs. Brad Glick, Yasmine Kirkorian and Adam Friedman.